“We are thrilled to have reached another key development milestone for our biosensor platform, particularly demonstrating a substantial TTR reduction from 120 to 30 seconds, far below our original target of over 1 minute per test,”
said Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions.
“Based on these successful results, the biosensor development team has now proceeded to its next testing phase, which will include testing human saliva.”
“We are thrilled to have reached another key development milestone for our biosensor platform, particularly demonstrating a substantial TTR reduction from 120 to 30 seconds, far below our original target of over 1 minute per test,”
said Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions.
“Based on these successful results, the biosensor development team has now proceeded to its next testing phase, which will include testing human saliva.”
CUL8R (*´∀｀*) gn8